AAPL   319.39 (-0.76%)
MSFT   181.78 (-0.57%)
FB   227.64 (-1.84%)
GOOGL   1,427.50 (-0.51%)
AMZN   2,453.87 (-0.69%)
NVDA   348.02 (-1.20%)
CGC   16.10 (-2.31%)
BABA   211.85 (+2.56%)
MU   45.80 (-1.19%)
GE   7.00 (+3.55%)
TSLA   882.49 (-1.74%)
AMD   52.45 (-2.20%)
T   30.93 (+0.00%)
NFLX   422.14 (-0.89%)
BAC   24.96 (+1.42%)
BA   152.30 (+0.60%)
AAPL   319.39 (-0.76%)
MSFT   181.78 (-0.57%)
FB   227.64 (-1.84%)
GOOGL   1,427.50 (-0.51%)
AMZN   2,453.87 (-0.69%)
NVDA   348.02 (-1.20%)
CGC   16.10 (-2.31%)
BABA   211.85 (+2.56%)
MU   45.80 (-1.19%)
GE   7.00 (+3.55%)
TSLA   882.49 (-1.74%)
AMD   52.45 (-2.20%)
T   30.93 (+0.00%)
NFLX   422.14 (-0.89%)
BAC   24.96 (+1.42%)
BA   152.30 (+0.60%)
AAPL   319.39 (-0.76%)
MSFT   181.78 (-0.57%)
FB   227.64 (-1.84%)
GOOGL   1,427.50 (-0.51%)
AMZN   2,453.87 (-0.69%)
NVDA   348.02 (-1.20%)
CGC   16.10 (-2.31%)
BABA   211.85 (+2.56%)
MU   45.80 (-1.19%)
GE   7.00 (+3.55%)
TSLA   882.49 (-1.74%)
AMD   52.45 (-2.20%)
T   30.93 (+0.00%)
NFLX   422.14 (-0.89%)
BAC   24.96 (+1.42%)
BA   152.30 (+0.60%)
AAPL   319.39 (-0.76%)
MSFT   181.78 (-0.57%)
FB   227.64 (-1.84%)
GOOGL   1,427.50 (-0.51%)
AMZN   2,453.87 (-0.69%)
NVDA   348.02 (-1.20%)
CGC   16.10 (-2.31%)
BABA   211.85 (+2.56%)
MU   45.80 (-1.19%)
GE   7.00 (+3.55%)
TSLA   882.49 (-1.74%)
AMD   52.45 (-2.20%)
T   30.93 (+0.00%)
NFLX   422.14 (-0.89%)
BAC   24.96 (+1.42%)
BA   152.30 (+0.60%)
Log in

NYSE:AGNAllergan Stock Price, Forecast & News

$193.02
0.00 (0.00 %)
(As of 06/2/2020 11:30 AM ET)
Add
Compare
Today's Range
$193.02
Now: $193.02
$193.02
50-Day Range
$175.71
MA: $187.39
$193.89
52-Week Range
$114.27
Now: $193.02
$202.21
VolumeN/A
Average Volume4.01 million shs
Market Capitalization$63.50 billion
P/E RatioN/A
Dividend Yield1.53%
Beta1.2
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; and strategic alliance and option agreement with Editas Medicine, Inc. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
Read More
Allergan logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 3.3Dividend Strength: 3.3Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.86 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP01849010
Phone862-261-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$16.09 billion
Cash Flow$36.70 per share
Book Value$177.28 per share

Profitability

Net Income$-5,271,000,000.00

Miscellaneous

Employees17,400
Market Cap$63.50 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive AGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AGN and its competitors with MarketBeat's FREE daily newsletter.

Allergan (NYSE:AGN) Frequently Asked Questions

How has Allergan's stock been impacted by COVID-19 (Coronavirus)?

Allergan's stock was trading at $185.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AGN shares have increased by 4.1% and is now trading at $193.02. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Allergan?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 12 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Allergan.

When is Allergan's next earnings date?

Allergan is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Allergan.

How were Allergan's earnings last quarter?

Allergan plc (NYSE:AGN) issued its earnings results on Monday, February, 10th. The company reported $5.22 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $4.57 by $0.65. The business had revenue of $4.35 billion for the quarter, compared to the consensus estimate of $4.09 billion. Allergan had a positive return on equity of 8.46% and a negative net margin of 15.44%. Allergan's revenue for the quarter was up 6.6% compared to the same quarter last year. During the same period last year, the company earned $4.29 EPS. View Allergan's earnings history.

How often does Allergan pay dividends? What is the dividend yield for Allergan?

Allergan announced a quarterly dividend on Wednesday, March 18th. Investors of record on Thursday, April 16th will be given a dividend of $0.74 per share on Monday, June 15th. This represents a $2.96 dividend on an annualized basis and a dividend yield of 1.53%. The ex-dividend date is Wednesday, April 15th. View Allergan's dividend history.

How will Allergan's stock buyback program work?

Allergan declared that its Board of Directors has authorized a stock buyback program on Tuesday, January 29th 2019, which permits the company to buyback $2,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 4.1% of its stock through open market purchases. Stock buyback programs are often a sign that the company's board believes its shares are undervalued.

What price target have analysts set for AGN?

13 analysts have issued 1 year target prices for Allergan's stock. Their forecasts range from $165.00 to $203.00. On average, they expect Allergan's stock price to reach $186.71 in the next twelve months. This suggests that the stock has a possible downside of 3.3%. View analysts' price targets for Allergan.

Has Allergan been receiving favorable news coverage?

News coverage about AGN stock has been trending very positive on Tuesday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Allergan earned a coverage optimism score of 3.5 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutAllergan.

Who are some of Allergan's key competitors?

What other stocks do shareholders of Allergan own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), United Rentals (URI) and Transocean (RIG).

Who are Allergan's key executives?

Allergan's management team includes the following people:
  • Mr. Brenton L. Saunders, Chairman, Pres & CEO (Age 49)
  • Mr. William Meury, Exec. VP & Chief Commercial Officer (Age 51)
  • Dr. C. David Nicholson, Exec. VP and Chief R&D Officer (Age 64)
  • Mr. Matthew M. Walsh, Exec. VP & CFO (Age 52)
  • Mr. Wayne R. Swanton, Exec. VP of Global Operations (Age 51)

What is Allergan's stock symbol?

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

Who are Allergan's major shareholders?

Allergan's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.42%), State Street Corp (4.15%), Longview Partners Guernsey LTD (1.52%), Clearbridge Investments LLC (1.24%), JPMorgan Chase & Co. (1.12%) and Morgan Stanley (0.84%). Company insiders that own Allergan stock include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi and Matthew M Walsh. View institutional ownership trends for Allergan.

Which institutional investors are selling Allergan stock?

AGN stock was sold by a variety of institutional investors in the last quarter, including Longview Partners Guernsey LTD, Nuveen Asset Management LLC, Clearbridge Investments LLC, State Street Corp, Segantii Capital Management Ltd, Scharf Investments LLC, Canyon Capital Advisors LLC, and Mackenzie Financial Corp. View insider buying and selling activity for Allergan.

Which institutional investors are buying Allergan stock?

AGN stock was bought by a variety of institutional investors in the last quarter, including Syquant Capital Sas, JPMorgan Chase & Co., ING Groep NV, BlackRock Inc., Water Island Capital LLC, Maso Capital Partners Ltd, Glazer Capital LLC, and Swiss National Bank. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi, and Matthew M Walsh. View insider buying and selling activity for Allergan.

How do I buy shares of Allergan?

Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Allergan's stock price today?

One share of AGN stock can currently be purchased for approximately $193.02.

How big of a company is Allergan?

Allergan has a market capitalization of $63.50 billion and generates $16.09 billion in revenue each year. The company earns $-5,271,000,000.00 in net income (profit) each year or $17.64 on an earnings per share basis. Allergan employs 17,400 workers across the globe.

What is Allergan's official website?

The official website for Allergan is www.allergan.com.

How can I contact Allergan?

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.